 BELLUS Health Inc NASDAQ: BLU is trading higher Monday after the company announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractory chronic cough. The stock is experiencing high volatility, trading as high as 4.78 and as low as 3.63 in todays session. 